- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05522829
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
A Randomized, Double-blind Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E-1 (Alpha/Beta/Delta/Omicron (BA.1/BA.4/BA.5) Variants S-Trimer COVID-19 Vaccine) in Population Aged 18 Years and Older
Study Overview
Status
Conditions
Detailed Description
The study is a randomized, double-blind Phase II study. It will evaluate the immunogenicity and safety of SCTV01E-1. Approximately 400 participants aged 18 years and older will be enrolled in this study.
160 participants who have not been vaccinated with any COVID-19 vaccine will be enrolled in Cohort 1 and randomly assigned to the Group SCTV01E-1 and Group SCTV01E in a ratio of 1:1. All participants will receive 3 doses of vaccinations: Vaccination 1 on D0, Vaccination 2 on D28 and Vaccination 3 on D150. Participants in Group SCTV01E-1 will receive 3 doses of SCTV01E-1, and participants in Group SCTV01E will receive 3 doses of SCTV01E.
240 participants who were fully vaccinated with 2 or 3 doses of inactivated COVID-19 vaccines at least three months ago will be enrolled in Cohort 2 and randomly assigned to Group SCTV01E-1 and Group SCTV01E in a ratio of 1:1. All participants will receive 2 doses of vaccinations: Vaccination 1 on D0 and Vaccination 2 on D120. Participants in Group SCTV01E-1 will receive 2 doses of SCTV01E-1, and participants in Group SCTV01E will receive 2 doses of SCTV01E.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Dilihumare ·Niyazi
- Phone Number: +86 10 58628288-9014
- Email: dilihumare_niyazi@sinocelltech.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged ≥18 years when signing ICF;
- For Cohort 1: Participants who have not been vaccinated with any COVID-19 vaccine; For Cohort 2: Participants who were fully vaccinated with 2 or 3 doses of inactivated COVID-19 vaccine and the interval between the last dose of previously vaccination and the 1st study vaccination is 3 to 24 months;
- Healthy participants or participants with pre-existing medical conditions that are in stable condition. The "pre-existing medical conditions" include but not limited to hypertension, diabetes, chronic cholecystitis and cholelithiasis, chronic gastritis, etc. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization as a consequence of worsening disease state for at least 3 months prior to study participation;
- The participant or his/her legal representative can sign written ICF, and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that are available if they do not participate in the trial;
- The participant can read, understand, and fill in record cards by himself/herself or with help;
- Fertile men and women of childbearing potential voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after the last dose of study vaccination.
Exclusion Criteria:
- Presence of fever (oral temperature ≥37.5℃) within 3 days before the 1st study vaccination;
- For Cohort 2 only: Known history of COVID-19 or asymptomatic SRAS-CoV-2 infection;
- A history of allergic reactions to any vaccines or drugs, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;
- Immunocompromised patients suffering from immunodeficiency diseases, significant diseases, or immune diseases (including Guillain-Barre Syndrome [GBS], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc;
- Long-term use of immunosuppressant therapy or immunomodulatory drugs for >14 days within the six months prior to enrollment. Whereas short-term (≤14 days) use of oral, inhaled and topical steroids are allowed;
- Those who have a history of HIV or tested positive for HIV;
- For Cohort 1, participants received any drugs or vaccines used to prevent COVID-19; for Cohort 2, participants received other drugs or vaccines used to prevent COVID-19 besides inactivated COVID-19 vaccines;
- A history of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), or related vaccination;
- A medical or family history of seizure, epilepsy, encephalopathy and psychosis;
- Presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (skin basal cell carcinoma and carcinoma in-situ of cervix are exceptions and will not be excluded), such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia;
- Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;
- Patients on antituberculosis therapy;
- Participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study;
- Participants who received other investigational drugs within 1 month before the study vaccination;
- Participants who have acute illness, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis;
- Participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination;
- Those who donated blood or had blood loss (≥450 mL) within 3 months before the vaccination or plan to donate blood during the study period;
- Those who are pregnant or breast-feeding or plan to be pregnant during the study period;
- Those who plan to donate ovum or sperms during the study period;
- Those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;
- Those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse or confound the study results, or non-conformance with the maximal benefits of the participants.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: Group SCTV01E-1
3 doses of SCTV01E-1
|
Day 0; intramuscular injection
Day 28; intramuscular injection
Day 150; intramuscular injection
|
Active Comparator: Cohort 1: Group SCTV01E
3 doses of SCTV01E
|
Day 0; intramuscular injection
Day 28; intramuscular injection
Day 150; intramuscular injection
|
Experimental: Cohort 2: Group SCTV01E-1
2 doses of SCTV01E-1
|
Day 0; intramuscular injection
Day 120; intramuscular injection
|
Active Comparator: Cohort 2: Group SCTV01E
2 doses of SCTV01E
|
Day 0; intramuscular injection
Day 120; intramuscular injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cohort 1: Geometric mean titers (GMT) of neutralizing antibodies (nAb) against Omicron subvariant (BA.5) on Day 42.
Time Frame: Day 42 after the study vaccination
|
Day 42 after the study vaccination
|
Cohort 1: Geometric mean titers (GMT) of neutralizing antibodies (nAb) against Omicron subvariant (BA.5) on Day 178.
Time Frame: Day 178 after the study vaccination
|
Day 178 after the study vaccination
|
Cohort 2: Geometric mean titers (GMT) of neutralizing antibodies (nAb) against Omicron subvariant (BA.5) on Day 28.
Time Frame: Day 28 after the study vaccination
|
Day 28 after the study vaccination
|
Cohort 2: Geometric mean titers (GMT) of neutralizing antibodies (nAb) against Omicron subvariant (BA.5) on Day 148.
Time Frame: Day 148 after the study vaccination
|
Day 148 after the study vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cohort 1: Seroresponse rates of nAb against Omicron subvariant (BA.5) on Day 42.
Time Frame: Day 42 after the study vaccination
|
Day 42 after the study vaccination
|
Cohort 1: Seroresponse rates of nAb against Omicron subvariant (BA.5) on Day 178.
Time Frame: Day 178 after the study vaccination
|
Day 178 after the study vaccination
|
Cohort 1: Incidence and severity of solicited AEs within 7 days after each of the study vaccination.
Time Frame: Day 0 to Day 7 after each of the study vaccination
|
Day 0 to Day 7 after each of the study vaccination
|
Cohort 1: Incidence and severity of unsolicited AEs within 28 days after each of the study vaccination.
Time Frame: Day 0 to Day 28 after each of the study vaccination
|
Day 0 to Day 28 after each of the study vaccination
|
Cohort 1: Incidence and severity of SAEs and AESIs within 180 days after each of the study vaccination.
Time Frame: During the whole study
|
During the whole study
|
Cohort 2: Seroresponse rates of nAb against Omicron subvariant (BA.5) on Day 28.
Time Frame: Day 28 after the study vaccination
|
Day 28 after the study vaccination
|
Cohort 2: Seroresponse rates of nAb against Omicron subvariant (BA.5) on Day 148.
Time Frame: Day 148 after the study vaccination
|
Day 148 after the study vaccination
|
Cohort 2: Incidence and severity of solicited AEs within 7 days after each of the study vaccination.
Time Frame: Day 0 to Day 7 after each of the study vaccination
|
Day 0 to Day 7 after each of the study vaccination
|
Cohort 2: Incidence and severity of unsolicited AEs within 28 days after each of the study vaccination.
Time Frame: Day 0 to Day 28 after each of the study vaccination
|
Day 0 to Day 28 after each of the study vaccination
|
Cohort 2: Incidence and severity of SAEs and AESIs within 180 days after each of the study vaccination.
Time Frame: During the whole study
|
During the whole study
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCTV01E-1-UAE-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on SCTV01E-1 on D0
-
SeqirusDepartment of Health and Human ServicesActive, not recruitingInfections | Virus Diseases | Respiratory Tract Infections | Influenza, Human | Infection ViralUnited States
-
University of OxfordBioinduction; Jon MoultonTrust; Placito BequestNot yet recruitingCentral Post Stroke Pain
-
Northwestern UniversityNational Institute on Minority Health and Health Disparities (NIMHD)CompletedDepression | Postpartum Depression | Perinatal DepressionUnited States
-
SeqirusCompletedInfections | RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases | Influenza, Human | Orthomyxoviridae Infections | Influenza in BirdsUnited States
-
Northwestern UniversityNational Institute on Minority Health and Health Disparities (NIMHD)CompletedPostpartum Depression | Perinatal DepressionUnited States
-
University of California, San DiegoMotherToBabyUnknownMental Disorders | Contraception | Chemical Teratogen ExposureUnited States
-
Aksaray University Training and Research HospitalCompletedAcute Coronary Syndrome
-
Centre hospitalier de l'Université de Montréal...CompletedPneumonia | Acute Respiratory Distress Syndrome | Pulmonary Embolism | Dyspnea | Hypoxemia | AtelectasisCanada
-
University of Southern CaliforniaRecruiting
-
Wake Forest University Health SciencesTerminatedUrinary Retention PostoperativeUnited States